NCT00003532 - Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 5, 1996

Primary Completion Date

October 18, 2002

Study Completion Date

October 18, 2002

Conditions

Stage III Ovarian CancerStage IV Ovarian Cancer

Interventions

DRUG

Antineoplaston therapy (Atengenal + Astugenal)

"Patients with Stage III or IV Ovarian Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston